ARROWHEAD PHARMACEUTICALS, INC. Accrued Liabilities, Current
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Accrued Liabilities, Current of $86.17 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Accrued Liabilities, Current $86.17M.
- 2026-03-31: Accrued Liabilities, Current $76.58M.
- 2025-12-31: Accrued Liabilities, Current $130.08M.
- 2025-09-30: Accrued Liabilities, Current $90.42M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $86.17M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $76.58M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $130.08M 10-Q · filed 2026-02-05 | |
| 2025-09-30 | $90.42M 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $64.82M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $78.45M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $59.40M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $63.02M 10-K · filed 2025-11-25 | |
| 2024-06-30 | $47.90M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $37.05M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $46.60M 10-Q · filed 2024-02-06 | |
| 2023-09-30 | $39.76M 10-K · filed 2024-11-26 | |
| 2023-06-30 | $38.19M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $39.55M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $48.17M 10-Q · filed 2023-02-06 | |
| 2022-09-30 | $46.86M 10-K · filed 2023-11-29 | |
| 2022-06-30 | $32.50M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $23.71M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $18.52M 10-Q · filed 2022-02-02 | |
| 2021-09-30 | $14.00M 10-K · filed 2022-11-28 | |
| 2021-06-30 | $29.52M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $12.86M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $9.57M 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $5.39M 10-K · filed 2021-11-22 | $5.39M 10-K · filed 2020-11-23 |
| 2020-06-30 | $9.41M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $4.42M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $3.99M 10-Q · filed 2020-02-05 | |
| 2019-09-30 | $6.50M 10-K · filed 2020-11-23 | |
| 2019-06-30 | $5.17M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $5.72M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $3.91M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $5.04M 10-K · filed 2019-11-25 | |
| 2018-06-30 | $2.16M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $4.13M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $3.48M 10-Q · filed 2018-02-09 | |
| 2017-09-30 | $4.56M 10-K · filed 2018-12-11 | |
| 2017-06-30 | $1.99M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $2.18M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $4.76M 10-Q · filed 2017-02-06 | |
| 2016-09-30 | $4.59M 10-K · filed 2017-12-12 | |
| 2016-06-30 | $6.26M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $3.83M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $3.92M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $5.38M 10-K · filed 2016-12-14 | |
| 2015-06-30 | $1.73M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $2.04M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $1.15M 10-Q · filed 2015-02-09 | |
| 2014-09-30 | $1.40M 10-K · filed 2015-12-14 | |
| 2014-06-30 | $1.07M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $913.86K 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $684.52K 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $638.88K 10-K · filed 2014-11-25 | |
| 2013-06-30 | $706.09K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $823.52K 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $842.64K 10-Q · filed 2013-02-13 | |
| 2012-09-30 | $730.77K 10-K · filed 2013-12-18 | |
| 2012-06-30 | $1.02M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $2.38M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $2.39M 10-Q · filed 2012-02-09 | |
| 2011-09-30 | $864.51K 10-K · filed 2012-12-28 | |
| 2011-06-30 | $472.28K 10-Q · filed 2011-08-08 | |
| 2010-09-30 | $494.74K 10-K · filed 2011-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |